SMITH BRAIN TRUST — Executives at pharmaceutical company Mylan have come under attack for giving themselves raises while boosting the price of a lifesaving injection device by more than 400 percent over the past nine years. Finance professor David Kass at the University of Maryland’s Robert H. Smith School of Business compares the situation to a 2015 scandal, when hedge fund manager and pharmaceutical CEO Martin Shkreli raised the price of the AIDS drug Daraprim from $13.50 a pill to $750. Mylan has raised the price of a two-dose package of EpiPen to $400. The price was $60 in 2007, the same year the firm purchased the auto-injector. The company also has a virtual monopoly on the product after a voluntary recall felled its only competitor. The product is used as a lifesaving injection device for those who suffer from severe allergies, including potentially fatal allergic reactions. Kass, a former federal government health economist, told San Francisco’s KCBS Radio that bipartisan action from Congress is not surprising over this latest pharmaceutical pricing controversy.
Media Contact
Greg Muraski
Media Relations Manager
301-405-5283
301-892-0973 Mobile
gmuraski@umd.edu
About the University of Maryland's Robert H. Smith School of Business
The Robert H. Smith School of Business is an internationally recognized leader in management education and research. One of 12 colleges and schools at the University of Maryland, College Park, the Smith School offers undergraduate, full-time and flex MBA, executive MBA, online MBA, business master’s, PhD and executive education programs, as well as outreach services to the corporate community. The school offers its degree, custom and certification programs in learning locations in North America and Asia.